Efficacy and safety of canagliflozin in patients with type 2 diabetes based on history of cardiovascular disease or cardiovascular risk factors: a post hoc analysis of pooled data

Table 1 Study design and patient population

Study	Inclusion criteria			Patients contributing data to pooled analysis, n
Study	Age, years	HbA1c, %	eGFR, mL/min/1.73 m²	PBO	CANA 100 mg	CANA 300 mg	Total
Monotherapy	18–80	7.0–10.0	≥50	192	195	197	584
Add-on to MET	18–80	7.0–10.5	≥55	183	368	367	918
Add-on to MET + SU	18–80	7.0–10.5	≥55	156	157	156	469
Add-on to MET + PIO	18–80	7.0–10.5	≥55	115	113	114	342
Overall total, N				646	833	834	2313

Data have been previously reported [19, 22, 24]
eGFR estimated glomerular filtration rate, PBO placebo, CANA canagliflozin, MET metformin, SU sulphonylurea, PIO pioglitazone

ISSN: 1475-2840